Title:
治療を増強するグルカン
Document Type and Number:
Japanese Patent JP4903041
Kind Code:
B2
Abstract:
This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.
Inventors:
Chung, Nai-Gong, Vi.
Application Number:
JP2006520398A
Publication Date:
March 21, 2012
Filing Date:
July 16, 2004
Export Citation:
Assignee:
Sloan-Kettering Institute for Cancer Research
International Classes:
A61K31/715; A61K39/395; A61K31/716; A61K31/739; A61K39/44; A61P35/00; A61P43/00
Domestic Patent References:
| JP63500805A |
Foreign References:
| US5250436 | ||||
| US4810646 |
Other References:
SANO, B., et al.,Antitumor Effects Induced by the Combination of TNP-470 as an Angiogenesis Inhibitor and Lentinan as a Biological Response Modifier in a Rabbit Spontaneous Liver Metastasis Model,SURGERY TODAY,2002年,Vol.32,p.503-509
瀧田雅仁, 他.,5'-DFUR・Lentinan併用により著明な肝転移縮小をみたThymidine Phosphorylase (dThdPase)陽性胃癌の1例,癌と化学療法,日本,1998年,Vol.25, No.1,p.129-133
CHEUNG, N-K.V., et al.,Oral (1→3),(1→4)-β-D-Glucan Synergizes with Antiganglioside GD2 Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma,Clinical Cancer Research,2002年 5月,Vol.8,p.1217-1223
CHEUNG NAI-KONG,Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies,CANCER IMMUNOLOGY IMMUNOTHERAPY,2002年11月,V51 N10,P557-564
KANEKO, Y., et al.,ACTIVITY OF LENTINAN AGAINST CANCER AND AIDS,International Journal of Immunotherapy,1989年,Vol.5, No.4,p.203-213
HYRLYN, D., et al.,STIMULATION OF MONOCLONAL ANTIBODY-DEPENDENT MACROPHAGE-MEDIATED CYTOTOXICITY AGAINST HUMAN TUMORS BY LENTINAN,INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY,1985年 1月 1日,Vol.7, No.3,p.332
瀧田雅仁, 他.,5'-DFUR・Lentinan併用により著明な肝転移縮小をみたThymidine Phosphorylase (dThdPase)陽性胃癌の1例,癌と化学療法,日本,1998年,Vol.25, No.1,p.129-133
CHEUNG, N-K.V., et al.,Oral (1→3),(1→4)-β-D-Glucan Synergizes with Antiganglioside GD2 Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma,Clinical Cancer Research,2002年 5月,Vol.8,p.1217-1223
CHEUNG NAI-KONG,Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies,CANCER IMMUNOLOGY IMMUNOTHERAPY,2002年11月,V51 N10,P557-564
KANEKO, Y., et al.,ACTIVITY OF LENTINAN AGAINST CANCER AND AIDS,International Journal of Immunotherapy,1989年,Vol.5, No.4,p.203-213
HYRLYN, D., et al.,STIMULATION OF MONOCLONAL ANTIBODY-DEPENDENT MACROPHAGE-MEDIATED CYTOTOXICITY AGAINST HUMAN TUMORS BY LENTINAN,INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY,1985年 1月 1日,Vol.7, No.3,p.332
Attorney, Agent or Firm:
Hideto Asamura
Hajime Asamura
Naganuma Akio
Yukihiro Ikeda
Hajime Asamura
Naganuma Akio
Yukihiro Ikeda